No Data
Beijing Hotgen Biotech Co.,Ltd (688068.SH): has cumulatively repurchased 0.93% of its shares.
On February 6, Gelonghui reported that Beijing Hotgen Biotech Co., Ltd (688068.SH) announced that as of January 31, 2025, the company repurchased 860,500 shares through the trading system of the Shanghai Stock Exchange via centralized bidding, accounting for 0.93% of the company's total share capital of 92,474,692 shares. The highest price of the repurchase was 80.80 yuan/share, the lowest price was 67.29 yuan/share, and the total funds paid amounted to 63,443,433.17 yuan (excluding stamp duty, transaction commissions, and other transaction fees).
The clinical trial application for the innovative drug AA001 monoclonal antibody developed by a subsidiary of Beijing Hotgen Biotech Co.,Ltd has been approved.
Beijing Hotgen Biotech Co.,Ltd (688068.SH) announced that the company's equity holding in Shenzhen Zhiyuan Biomedical Co., Ltd. (abbreviated...)
Beijing Hotgen Biotech Co.,Ltd (688068.SH): Recently obtained 17 overseas qualification certifications.
Gelonghui, January 17 – Beijing Hotgen Biotech Co., Ltd (688068.SH) announced that the company recently obtained 17 qualifications for Overseas certification. The acquisition of these qualifications has enriched the variety of products, further improved the menu of the company's in vitro diagnostic products, while actively responding to the demands of overseas markets, facilitating the company's ability to expand its market, and enhancing its core competitiveness.
Hejing Biotech: Beijing Hejing Biotechnology Co., Ltd. 2024 Annual Results Forecast
Beijing Hejing Biotechnology Co., Ltd. 2024 Annual Results Forecast
High R&D investment and a decline in the terminal hospitalization price of products have resulted in Beijing Hotgen Biotech Co., Ltd turning from profit to loss in 2024, with Q4 net profit decreasing almost fivefold year-on-year.
① Regarding the main reasons for the decline in performance, Beijing Hotgen Biotech Co.,Ltd attributes it to high R&D investment, intensified competition in the Industry, and increased R&D investment from joint ventures. ② As medical centralized procurement continues to advance, competition within the Industry intensifies, leading to further declines in the terminal hospitalization prices of products, and Beijing Hotgen Biotech Co.,Ltd's single machine revenue and output rate have shown varying degrees of decline.
